346 related articles for article (PubMed ID: 26374199)
1. Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.
Narayan R; Garcia JS; Percival ME; Berube C; Coutre S; Gotlib J; Greenberg P; Liedtke M; Hewitt R; Regan K; Williamson C; Doykan C; Cardone MH; McMillan A; Medeiros BC
Leuk Lymphoma; 2016; 57(3):609-15. PubMed ID: 26374199
[TBL] [Abstract][Full Text] [Related]
2. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
[TBL] [Abstract][Full Text] [Related]
3. Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML).
Kenealy M; Patton N; Filshie R; Nicol A; Ho SJ; Hertzberg M; Mills T; Prosser I; Link E; Cowan L; Zannino D; Seymour JF
Leuk Lymphoma; 2017 Feb; 58(2):298-307. PubMed ID: 27268068
[TBL] [Abstract][Full Text] [Related]
4. Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?
Platzbecker U; Germing U
Leukemia; 2013 Sep; 27(9):1813-9. PubMed ID: 23644421
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine.
Zeidan AM; Al Ali NH; Padron E; Lancet J; List A; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):705-10. PubMed ID: 26440749
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia.
Zeidan AM; Smith BD; Carraway HE; Gojo I; DeZern A; Gore SD
Br J Haematol; 2017 Jan; 176(2):241-247. PubMed ID: 27790720
[TBL] [Abstract][Full Text] [Related]
7. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Raza A; Mehdi M; Mumtaz M; Ali F; Lascher S; Galili N
Cancer; 2008 Oct; 113(7):1596-604. PubMed ID: 18720364
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.
Prebet T; Charbonnier A; Gelsi-Boyer V; Mozziconacci MJ; Blaise D; Vey N
Leuk Lymphoma; 2013 Jul; 54(7):1538-40. PubMed ID: 23110702
[No Abstract] [Full Text] [Related]
9. A systematic review and meta
Kunacheewa C; Thongthang P; Ungprasert P; Utchariyaprasit E; Owattanapanich W
Hematology; 2019 Dec; 24(1):498-506. PubMed ID: 31221030
[TBL] [Abstract][Full Text] [Related]
10. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.
Sekeres MA; Othus M; List AF; Odenike O; Stone RM; Gore SD; Litzow MR; Buckstein R; Fang M; Roulston D; Bloomfield CD; Moseley A; Nazha A; Zhang Y; Velasco MR; Gaur R; Atallah E; Attar EC; Cook EK; Cull AH; Rauh MJ; Appelbaum FR; Erba HP
J Clin Oncol; 2017 Aug; 35(24):2745-2753. PubMed ID: 28486043
[TBL] [Abstract][Full Text] [Related]
11. Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis.
Stevens B; Winters A; Gutman JA; Fullerton A; Hemenway G; Schatz D; Miltgen N; Wei Q; Abbasi T; Vali S; Singh NK; Drusbosky L; Cogle CR; Hammes A; Abbott D; Jordan CT; Smith C; Pollyea DA
Leuk Res; 2019 Jun; 81():43-49. PubMed ID: 31009835
[TBL] [Abstract][Full Text] [Related]
12. Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Attar EC; Amrein PC; Fraser JW; Fathi AT; McAfee S; Wadleigh M; Deangelo DJ; Steensma DP; Stone RM; Foster J; Neuberg D; Ballen KK
Leuk Res; 2013 Sep; 37(9):1016-20. PubMed ID: 23773898
[TBL] [Abstract][Full Text] [Related]
13. Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia.
Kenealy M; Hertzberg M; Benson W; Taylor K; Cunningham I; Stevenson W; Hiwase D; Eek R; Zantomio D; Jong S; Wall M; Blombery P; Gerber T; Debrincat M; Zannino D; Seymour JF
Haematologica; 2019 Apr; 104(4):700-709. PubMed ID: 30545923
[TBL] [Abstract][Full Text] [Related]
14. Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia.
Wei A; Tan P; Perruzza S; Govindaraj C; Fleming S; McManus J; Avery S; Patil S; Stevenson W; Plebanski M; Spencer A
Br J Haematol; 2015 Apr; 169(2):199-210. PubMed ID: 25643589
[TBL] [Abstract][Full Text] [Related]
15. Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia.
Pollyea DA; Kohrt HE; Gallegos L; Figueroa ME; Abdel-Wahab O; Zhang B; Bhattacharya S; Zehnder J; Liedtke M; Gotlib JR; Coutre S; Berube C; Melnick A; Levine R; Mitchell BS; Medeiros BC
Leukemia; 2012 May; 26(5):893-901. PubMed ID: 22033493
[TBL] [Abstract][Full Text] [Related]
16. Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia.
Medeiros BC; McCaul K; Kambhampati S; Pollyea DA; Kumar R; Silverman LR; Kew A; Saini L; Beach CL; Vij R; Wang X; Zhong J; Gale RP
Haematologica; 2018 Jan; 103(1):101-106. PubMed ID: 29097499
[TBL] [Abstract][Full Text] [Related]
17. Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.
Mittelman M; Filanovsky K; Ofran Y; Rosenbaum H; Raanani P; Braester A; Goldschmidt N; Kirgner I; Herishanu Y; Perri C; Ellis M; Oster HS;
Ann Hematol; 2016 Oct; 95(11):1811-8. PubMed ID: 27546027
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
Liu W; Zhou Z; Chen L; Wang X
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
[TBL] [Abstract][Full Text] [Related]
19. Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?
Zeidan AM; Gore SD; Komrokji RS
Expert Rev Hematol; 2013 Jun; 6(3):251-4. PubMed ID: 23782079
[TBL] [Abstract][Full Text] [Related]
20. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.
Bello C; Yu D; Komrokji RS; Zhu W; Wetzstein GA; List AF; Lancet JE
Cancer; 2011 Apr; 117(7):1463-9. PubMed ID: 21425147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]